

**Group officers:**

Chair	Dr. Judith Kroep Leiden University (LUMC)
Secretary	Dr. Giorgio Bogani Istituto tumori Milano
Treasurer	Prof.dr. Fernanda Herrera Lausanne – CHUV

**EORTC Gynecological Cancer Group Fall Meeting**  
**8 November 2024**  
*Hybrid event*

<p align="center"><b>Friday, 8 November 2024</b> EORTC HQ (Brussels, Belgium) MS Teams</p>		
Time slot	Topic / Title of presentation	Speaker
<b>10:30-10:50</b>	<b>GCG update</b>	
'10	Welcome	Judith Kroep, GCG chair <i>LUMC, Leiden, NL</i>
'10	Secretary report	Giorgio Bogani, GCG secretary <i>IRCCS - Fondazione Istituto Nazionale dei Tumori, Milano, IT</i>
'10	Treasurer report	Fernanda Herrera, GCG treasurer <i>CHUV, Lausanne, CH</i>
<b>10:50-11:30</b>	<b>Trial Collaborations</b>	
15'	<b>EORTC-2133-QLG</b> <i>The Update of the EORTC QLQ-Ovarial cancer Module (EORTC-QLQ-OV28) Phase I</i>	Vesna Bjelic-Radisic, study coordinator <i>Helios Klinikum, Wuppertal, DE</i>
10'	<b>EORTC-1748-QLG-BCG-LYMG-GCG-GUCG</b> <i>Phase 1-3 development of an EORTC module assessing fertility issues and patient care needs</i>	Joachim Weis, study coordinator <i>Universitaetsklinikum Freiburg, Freiburg, DE</i> <b>TBC</b>
5'	<b>EORTC-1212-GCG</b> <i>A Randomised Phase II Study of Nintedanib (BIBF 1120) compared to Chemotherapy in</i>	Corneel Coens, EORTC statistician <i>On behalf of J. Tromp and A. Westermann</i>

**Group officers:**

Chair	Dr. Judith Kroep Leiden University (LUMC)
Secretary	Dr. Giorgio Bogani Istituto tumori Milano
Treasurer	Prof.dr. Fernanda Herrera Lausanne – CHUV

	<i>Patients with Recurrent Clear Cell Carcinoma of the Ovary or Endometrium (NiCCC)</i>	
10'	<b>EORTC-55102-GCG</b> <i>A phase III Trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high-risk endometrial cancer.</i>	Antonio Casado <i>Hospital Universitario San Carlos, Madrid, ES</i> <i>On behalf of Mansoor Raza Mirza</i>
<b>11:30-12:45</b>	<b>Closed and open trials</b>	
20'	<b>EORTC 62113-55115-STBSG-GCG</b> <i>A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment</i>	Isabelle Ray-Coquard, study coordinator <i>Centre Leon Berard, Lyon, FR</i>  Nick Reed, study coordinator <i>Gartnavel General Hospital, Glasgow, UK</i> <b>TBC</b>
5'	<b>EORTC 1508-GCG</b> <i>A phase II study of the anti-PD-L1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma</i>	Corneel Coens, EORTC statistician <i>On behalf of Susana Banerjee</i>
15'	<b>EORTC 55994-GCG</b> <i>Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa &gt; 4 cm or IIb cervical cancer.</i>	Stefano Greggi, study coordinator <i>IRCCS - Fondazione G. Pascale, Napoli, IT</i> <b>TBC</b>
10'	<b>EORTC 55092-GCG</b> <i>Phase IB-II, open label, multicentre feasibility study of Pazopanib in combination with Paclitaxel and Carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma.</i>	Ingrid Boere <i>Erasmus MC</i> <i>Rotterdam, NL</i>

**Group officers:**

Chair	Dr. Judith Kroep Leiden University (LUMC)
Secretary	Dr. Giorgio Bogani Istituto tumori Milano
Treasurer	Prof.dr. Fernanda Herrera Lausanne – CHUV

10'	<b>EORTC 1514-QLG-GCG</b> <i>Follow-up in Gynecological Cancer Survivors: An EORTC QLG-GCG Survivorship Study</i>	Antonio Casado, study coordinator <i>Hospital Universitario San Carlos, Madrid, ES</i>
12:45-14:00	<b>Lunch break</b>	
14:00-14:30	<b>Update GCG Y-ECI</b>	Ainhoa Madariaga, GCG Y-ECI chair <i>Hospital Universitario 12 De Octubre, Madrid, ES</i>
14:30--15:10	<b>Status new studies</b>	
'10	<i>Rare Cancers in Gynecologic Oncology ENGOT Registry</i>	Gloria Marquina, GCG represent ENGOT <i>Hospital Universitario San Carlos, Madrid, ES</i>
'5	<i>Phase 2 study of ctDNA guided immune check point-based treatment in MSI-high/dMMR endometrial cancer. A proposal from SAKK</i>	Ilaria Colombo, study coordinator <i>Ospedale San Giovanni, Bellinzona, CH</i>
'10	<i>Combined Approaches for Radiotherapy and Chemo- Immunotherapy in oligo-metastatic Cervical Cancer (CARE): a prospective, pragmatic, randomized phase III trial</i>	Giorgio Bogani, study coordinator <i>IRCCS - Fondazione Istituto Nazionale dei Tumori, Milano, IT</i>
'5	<i>Destiny-Ovarian02: Phase II T-DXd in PSROC ENGOT</i>	Judith Kroep, GCG chair <i>LUMC, Leiden, NL</i>
8'	<i>De-escalation and optimisation of Radiotherapy Volume to Improve Quality of Life and Reduce Toxicity in frail/elderly population. A platform trial (DETOX trial)</i>	Dr Hoda Abdel-Aty  <i>The Royal Marsden Hospital</i>
15:10-15:20	<b>Closing remarks</b>	



***Group officers:***

Chair	Dr. Judith Kroep Leiden University (LUMC)
Secretary	Dr. Giorgio Bogani Istituto tumori Milano
Treasurer	Prof.dr. Fernanda Herrera Lausanne – CHUV